Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00183989 · ClinicalTrials.gov registry record · Phase 2
Combination Therapy With Fludarabine, Mitoxantrone and Rituximab in Mantle Cell Lymphoma
A Phase 2 study, sponsored by University of Southern California.
- Terminated
- Registry status
- Phase 2
- Development phase
- 30
- Enrollment target
NCT00183989 is a Phase 2 study that was terminated before completion, run by University of Southern California. The registered enrollment target is 30 participants.
The verdict
NCT00183989, a Phase 2 study, was terminated before completion, sponsored by University of Southern California.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 30 participants
- Enrollment target
Study Summary
This study is being done in order to determine the effectiveness of the combination of fludarabine, mitoxantrone, and rituximab in patients with mantle cell lymphoma. All three drugs,fludarabine, mitoxantrone, and rituximab have been approved by the U.S. Food and Drug Administration (FDA)for the treatment of certain types of lymphoma. Rituximab is a drug (called a monoclonal antibody) which has anti-tumor activity on certain types of lymphoma. The combination of chemotherapy (fludarabine and mitoxantrone) with rituximab has not yet been investigated in patients with mantle cell lymphoma and therefore the combination in investigational.
Interventions
- DRUG Fludarabine, Mitoxantrone and Rituximab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2000-08 |
| Est. Completion | 2006-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00183989
The ClinicalTrials.gov registry entry for NCT00183989 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Southern California, which has 617 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Fludarabine, Mitoxantrone and Rituximab is the first listed.
NCT00183989 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00183989 about?
NCT00183989 is a clinical study titled "Combination Therapy With Fludarabine, Mitoxantrone and Rituximab in Mantle Cell Lymphoma". This study is being done in order to determine the effectiveness of the combination of fludarabine, mitoxantrone, and rituximab in patients with mantle cell lymphoma. All three drugs,fludarabine, mitoxantrone, and rituximab have been approved by the U.S. Food and Drug Administration (FDA)for the tre...
What is the current status of trial NCT00183989?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2000-08. Estimated completion is 2006-12.
What interventions are being tested in trial NCT00183989?
The interventions under investigation include: Fludarabine, Mitoxantrone and Rituximab (DRUG).
Who is sponsoring clinical trial NCT00183989?
This trial is sponsored by University of Southern California, which has 617 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.